Improvement of vascular function by acute and chronic treatment with the PDE-5 inhibitor sildenafil in experimental diabetes mellitus

British Journal of Pharmacology

Volumn 153, Issue 5, 2008, Pages 886-893

  Schafer A ^a   Fraccarollo, D ^a   Pfortsch S ^a   Flierl, U ^a   Vogt, C ^a   Pfrang, J ^a   Kobsar, A ^a   Renne T ^a   Eigenthaler, M ^a   Ertl, G ^a   Bauersachs, J ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Diabetes; Endothelial function; Nitric oxide; Oxygen radicals; Phosphodiesterase 5

Indexed keywords

ACETYLCHOLINE; ARGININE DERIVATIVE; GLYCOPROTEIN GP 91; N NITRO LEVO ARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; RAC PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SILDENAFIL; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; VASODILATATION;

EID: 40149096669     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707459     Document Type: Article

References (30)

1. Alp NJ, Mussa S, Khoo J, Cai S, Guzik T, Jefferson A et al. (2003). Tetrahydrobiopterin‐dependent preservation of nitric oxide‐mediated endothelial function in diabetes by targeted transgenic GTP‐cyclohydrolase I over‐expression. J Clin Invest 112: 725–735.
2. Basu A, Ryder REJ (2004). New treatment options for erectile dysfunction in patients with diabetes mellitus. Drugs 64: 2667–2688.
3. Bauersachs J, Schäfer A (2005). Tetrahydrobiopterin and eNOS dimer/monomer ratio—a clue to eNOS uncoupling in diabetes Cardiovasc Res 65: 768–769.
4. Cai S, Khoo J, Mussa S, Alp NJ, Channon KM (2005). Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia 48: 1933–1940.
5. De Angelis L, Marfella MA, Siniscalchi M, Marino L, Nappo F, Giugliano F et al. (2001). Erectile and endothelial dysfunction in Type II diabetes: a possible link. Diabetologia 44: 1155–1160.
6. Forstermann U, Munzel T (2006). Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113: 1708–1714.
7. Gross GJ (2005). Sildenafil and endothelial dysfunction in humans. Circulation 111: 721–723.
8. Guerci B, Bohme P, Kearney‐Schwartz A, Zannad F, Drouin P (2001). Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab 27: 436–447.
9. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R et al. (2002). Mechanisms of increased vascular superoxide production in human diabetes mellitus: role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105: 1656–1662.
10. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998). Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229–234.
11. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE et al. (2002). The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 40: 1232–1240.
12. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M et al. (2001). Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res 88: e14–e22.
13. Hryniewicz K, Dimayuga C, Hudaihed A, Androne AS, Zheng H, Jankowski K et al. (2005). Inhibition of angiotensin‐converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci (London) 108: 331–338.
14. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE (2002). Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 25: 1129–1134.
15. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ (2004). Impaired brachial artery endothelium‐dependent and ‐independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 43: 179–184.
16. Kimura M, Higashi Y, Hara K, Noma K, Sasaki S, Nakagawa K et al. (2003). PDE5 inhibitor sildenafil citrate augments endothelium‐dependent vasodilation in smokers. Hypertension 41: 1106–1110.
17. Koupparis AJ, Jeremy JY, Muzaffar S, Persad R, Shukla N (2005). Sildenafil inhibits the formation of superoxide and the expression of gp47 NAD(P)H oxidase induced by the thromboxane A2 mimetic, U46619, in corpus cavernosal smooth muscle cells. BJU Int 96: 423–427.
18. Landmesser U, Harrison D, Drexler H (2006). Oxidant stress−a major cause of reduced endothelial nitric oxide availability in cardiovascular disease. Eur J Clin Pharmacol 62: 13–19.
19. Li J, Li W, Altura BT, Altura BM (2005). Peroxynitrite‐induced relaxation in isolated rat aortic rings and mechanisms of action. Toxicol Appl Pharmacol 209: 269–276.
20. Milani E, Nikfar S, Khorasani R, Zamani MJ, Abdollahi M (2005). Reduction of diabetes‐induced oxidative stress by phosphodiesterase inhibitors in rats. Comp Biochem Physiol C Toxicol Pharmacol 140: 251–255.
21. Muzaffar S, Shukla N, Jeremy JY (2005a). Nicotinamide adenine dinucleotide phosphate oxidase: a promiscuous therapeutic target for cardiovascular drugs Trends Cardiovasc Med 15: 278–282.
22. Muzaffar S, Shukla N, Srivastava A, Angelini GD, Jeremy JY (2005b). Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells. Br J Pharmacol 146: 109–117.
23. Oliver JJ, Melville VP, Webb DJ (2006). Effect of regular phosphodiesterase type 5 inhibition in hypertension. Hypertension 48: 622–627.
24. Pegge NC, Twomey AM, Vaughton K, Gravenort MB, Ramsey MW, Price DE (2006). The role of endothelial dysfunction in the pathophysiology of erectile dysfunction in diabetes and in determining response to treatment. Diabet Med 23: 873–878.
25. Schäfer A, Fraccarollo D, Hildemann S, Tas P, Ertl G, Bauersachs J (2003). Addition of the selective aldosterone receptor antagonist eplerenone to ACE inhibition in heart failure: effect on endothelial function. Cardiovasc Res 58: 655–662.
26. Shukla N, Jones R, Persad R, Angelini GD, Jeremy JY (2005). Effect of sildenafil citrate and a nitric oxide donating sildenafil derivative, NCX 911, on cavernosal relaxation and superoxide formation in hypercholesterolaemic rabbits. Eur J Pharmacol 517: 224–231.
27. Tschoepe D, Menart‐Houtermans B (2002). Diabetes mellitus. In: Michelson AD (ed). Platelets. Academic Press: San Diego, pp 435–445.
28. Vlachopoulos C, Tsekoura D, Alexopoulos N, Panagiotakos D, Aznaouridis K, Stefanadis C (2004). Type 5 phosphodiesterase inhibition by sildenafil abrogates acute smoking‐induced endothelial dysfunction. Am J Hypertens 17: 1040–1044.
29. Wagenknecht LE, Zaccaro D, Espeland MA, Karter AJ, O'Leary DH, Haffner SM (2003). Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. Arterioscler Thromb Vasc Biol 23: 1035–1041.
30. Zobali F, Cakici I, Karasu C (2001). Effects of peroxynitrite on the reactivity of diabetic rat aorta. Pharmacology 63: 58–64.